PolyPid Ltd., un'azienda farmaceutica in fase clinica, sviluppa, produce e commercializza prodotti basati sulla piattaforma della matrice di incapsulamento polimero-lipidica (PLEX) per rispondere a esigenze mediche insoddisfatte. Il suo principale prodotto candidato è D-PLEX100, che aiuta a prevenire le infezioni del sito chirurgico (SSI) sternali (ossee) e le SSI addominali (dei tessuti molli). L'azienda sta inoltre sviluppando OncoPLEX, per il trattamento del cancro intra-tumorale. PolyPid Ltd. è stata costituita nel 2008 e ha sede a Petah Tikva, in Israele.
Nome | Titolo | Dal | Età |
|---|---|---|---|
| Brooke Story | Independent Non-Employee Chairman of the Board | 2025 | 55 |
| Dikla Czaczkes Akselbrad | CEO & Director | 2022 | 53 |
| Itzhak Krinsky | Independent Non-Employee Director | 2019 | 73 |
| Nir Dror | Independent Non-Employee Director | 2025 | 50 |
| Yechezkel Barenholz | Independent Non-Employee Director | 2008 | 84 |
| Yafit Stark | Clinical Development Strategy Advisor | 2008 | 71 |
| Noam Emanuel | Member of Scientific Advisory Board of Drug Delivery | 2024 | 67 |
| Moshe Salai | Member of Scientific Advisory Board | - | - |
| Erez Kachel | Member of Scientific Advisory Board | - | - |
| Hartzell V. Schaff | Member of Scientific Advisory Board | 2017 | - |
| Robert Benjamin Stein | Independent Non-Employee Director | 2020 | 75 |
| Frederick F. Lang | Member of Scientific Advisory Board | 2021 | - |
| Mitchel S. Berger | Member of Scientific Advisory Board | 2022 | 73 |
| Joseph BenAmram | Independent Non-Employee Director | 2023 | 61 |
| Raanan Berger | Member of Scientific Advisory Board of Oncology | 2024 | - |
| Yitzchak Jacobovitz | Independent Non-Employee Director | 2025 | 50 |